Cullinan Oncology IncNASDAQ:CGEM
- LAST PRICE11.5800
- TODAY'S CHANGE (%)-0.0600 (-0.5155%)
- Bid / Lots11.0000/ 3
- Ask / Lots15.0000/ 1
- Open / Previous Close11.6800 / 11.6400
- Day Range
- 52 Week Range
- Volume136,611
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CGEM |
|---|---|---|
| 09:32 ET | 517 | 11.53 |
| 09:33 ET | 100 | 11.48 |
| 09:42 ET | 100 | 11.74 |
| 09:50 ET | 100 | 11.74 |
| 09:51 ET | 100 | 11.75 |
| 09:53 ET | 500 | 11.745 |
| 09:57 ET | 200 | 11.94 |
| 10:06 ET | 100 | 11.91 |
| 10:08 ET | 100 | 11.81 |
| 10:11 ET | 700 | 11.84 |
| 10:20 ET | 1400 | 11.86 |
| 10:26 ET | 300 | 11.9 |
| 10:27 ET | 200 | 11.875 |
| 10:29 ET | 1800 | 11.85 |
| 10:36 ET | 1404 | 11.88 |
| 10:40 ET | 100 | 11.835 |
| 10:44 ET | 215 | 11.75 |
| 10:47 ET | 100 | 11.84 |
| 10:54 ET | 200 | 11.72 |
| 11:00 ET | 100 | 11.645 |
| 11:07 ET | 400 | 11.71 |
| 11:14 ET | 100 | 11.77 |
| 11:20 ET | 200 | 11.77 |
| 11:21 ET | 200 | 11.77 |
| 11:34 ET | 240 | 11.785 |
| 11:41 ET | 100 | 11.785 |
| 11:45 ET | 100 | 11.81 |
| 11:50 ET | 200 | 11.89 |
| 11:52 ET | 786 | 11.86 |
| 11:54 ET | 134 | 11.88 |
| 11:57 ET | 200 | 11.8 |
| 12:01 ET | 288 | 11.82 |
| 12:06 ET | 800 | 11.72 |
| 12:08 ET | 200 | 11.72 |
| 12:10 ET | 100 | 11.725 |
| 12:12 ET | 100 | 11.71 |
| 12:17 ET | 300 | 11.715 |
| 12:19 ET | 1000 | 11.72 |
| 12:37 ET | 300 | 11.7 |
| 12:39 ET | 200 | 11.655 |
| 12:44 ET | 100 | 11.685 |
| 12:51 ET | 100 | 11.7 |
| 12:57 ET | 1900 | 11.68 |
| 01:00 ET | 200 | 11.695 |
| 01:02 ET | 646 | 11.6838 |
| 01:06 ET | 200 | 11.695 |
| 01:15 ET | 600 | 11.68 |
| 01:33 ET | 100 | 11.665 |
| 01:49 ET | 400 | 11.64 |
| 01:51 ET | 900 | 11.625 |
| 01:54 ET | 800 | 11.5 |
| 01:56 ET | 600 | 11.5 |
| 01:58 ET | 800 | 11.46 |
| 02:00 ET | 1528 | 11.545 |
| 02:02 ET | 800 | 11.47 |
| 02:05 ET | 200 | 11.45 |
| 02:07 ET | 1100 | 11.56 |
| 02:09 ET | 200 | 11.535 |
| 02:14 ET | 877 | 11.595 |
| 02:16 ET | 200 | 11.61 |
| 02:18 ET | 200 | 11.59 |
| 02:20 ET | 300 | 11.59 |
| 02:21 ET | 302 | 11.64 |
| 02:23 ET | 100 | 11.59 |
| 02:25 ET | 400 | 11.65 |
| 02:32 ET | 1300 | 11.57 |
| 02:34 ET | 200 | 11.52 |
| 02:38 ET | 500 | 11.61 |
| 02:39 ET | 300 | 11.63 |
| 02:41 ET | 700 | 11.7 |
| 02:43 ET | 100 | 11.65 |
| 02:45 ET | 200 | 11.655 |
| 02:48 ET | 700 | 11.74 |
| 02:50 ET | 200 | 11.69 |
| 02:54 ET | 4363 | 11.71 |
| 02:56 ET | 100 | 11.71 |
| 02:57 ET | 100 | 11.715 |
| 02:59 ET | 600 | 11.7 |
| 03:03 ET | 620 | 11.72 |
| 03:06 ET | 1300 | 11.73 |
| 03:08 ET | 2300 | 11.7 |
| 03:10 ET | 100 | 11.72 |
| 03:15 ET | 700 | 11.65 |
| 03:17 ET | 100 | 11.69 |
| 03:19 ET | 200 | 11.7 |
| 03:21 ET | 404 | 11.7 |
| 03:24 ET | 200 | 11.71 |
| 03:26 ET | 100 | 11.7 |
| 03:28 ET | 100 | 11.71 |
| 03:30 ET | 1600 | 11.72 |
| 03:33 ET | 400 | 11.695 |
| 03:35 ET | 1100 | 11.71 |
| 03:37 ET | 1976 | 11.71 |
| 03:39 ET | 400 | 11.68 |
| 03:42 ET | 100 | 11.72 |
| 03:44 ET | 1000 | 11.705 |
| 03:48 ET | 538 | 11.69 |
| 03:50 ET | 497 | 11.65 |
| 03:51 ET | 300 | 11.605 |
| 03:53 ET | 1100 | 11.55 |
| 03:55 ET | 800 | 11.53 |
| 03:57 ET | 1800 | 11.54 |
| 04:00 ET | 1942 | 11.58 |
Today
Jan 24, 2023
Cullinan Oncology Says US FDA Approves Investigational New Drug Application for CLN-978, from 4:14PM ET on Tuesday Jan 24, 2023 by MT Newswires
4:14PM ET on Tuesday Jan 24, 2023 by MT NewswiresBUZZ-U.S. STOCKS ON THE MOVE-Baudax Bio , GATX Corp, Verb Technology, Decibel Therapeutics , from 2:07PM ET on Tuesday Jan 24, 2023 by Thomson Reuters
2:07PM ET on Tuesday Jan 24, 2023 by Thomson ReutersBUZZ-U.S. STOCKS ON THE MOVE-PACCAR, Cullinan Oncology, 3M, Peloton , from 11:25AM ET on Tuesday Jan 24, 2023 by Thomson Reuters
11:25AM ET on Tuesday Jan 24, 2023 by Thomson ReutersBRIEF-Cullinan Oncology Announces U.S. FDA Clearance Of Investigational New Drug Application For Cln-978, A Novel T-Cell Engager For The Treatment Of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, from 8:17AM ET on Tuesday Jan 24, 2023 by Thomson Reuters
8:17AM ET on Tuesday Jan 24, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cullinan Oncology Inc | 457.7M | 5.3x | --- |
Atara Biotherapeutics Inc | 481.0M | -2.1x | --- |
Arbutus Biopharma Corp | 471.0M | -6.0x | --- |
Caribou Biosciences Inc | 439.8M | -5.0x | --- |
Mesoblast Ltd | 494.3M | -5.5x | --- |
GH Research PLC | 462.5M | -27.4x | --- |
Company Information
Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
Contact Information
- Headquarters
- One Main Street, Suite 1350CAMBRIDGE, MA, United States 02142
- Phone
- 617-410-4650
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Anthony Rosenberg
- President, Chief Executive Officer, Director
- Nadim Ahmed
- Co-Founder, Acting Chief Scientific Officer
- Patrick Baeuerle
- Chief Financial Officer, Treasurer
- Jeffrey Trigilio
- Chief Medical Officer
- Jeffrey Jones
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $2.19 |
Book Value | $9.59 |
P/E Ratio | 5.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 4.5x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
